Ohvem Sales Corporation

Advanced platform for redefining flexibility in tortuous anatomy

Ideal Flexible Approach
Yukon Choice Flex offers new generation delivery system with ‘Flexi’platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System
The customized 2-Connector stent design of Yukon Choice Flex with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube
The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.

Resources
Product Brochure

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.

Comparison of clinical outcomes at 10 years in patients treated with new-generationBP-SES versus new-generation PP-EES versus early generation SES.

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from 3 randomised trials.

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials

We are amongst the most prominent enterprise actively engaged in offering a comprehensive assortment of Stents Drug Eluting. In order to manufacture these products, we are backed by a team of our adept workers, possessing years of experience in their concerned domain. Being a quality-centric firm, we verify these products upon numerous parameters in compliance with the set industrial standards to provide optimum satisfaction. Apart from this, these are available in various sizes & lengths as per the multifarious specifications of our clients.
Features:

• Perfect finish
• Optimum strength
• Durability

Future Beyond Polymers

Polymers (Durable or Biocompatible) are an integral part of Drug Release Matrix in current generation DES as they ensure the Release Kinetics of the active drug, the critical determinant of antirestenotic efficacy. However, the mechanical properties of the Metallic Cage and Aggressive Inflammatory Reactions during polymer erosion are known to cause.

• Persistent Fibrin Deposition
• Delayed Endothelialisation
• Chronic Inflammation
• Persistent Platelet Activation

Current DES Polymers are often associated with Flaking, Webbing and Peeling which leads to impaired action of active drug.

VIVO ISAR is an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol

Sirolimus:It is a well-studied and clinically proven Immunosuppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).Probucol:

It is historically proven to impose anti-restenosis effects through anti-oxidative and direct anti-proliferative effects. Though in VIVO ISAR, it is not used as an Active Pharmaceutical Ingredient.

Probucol here mimics the role of a Polymer thus functioning as a drug carrier. Probucol is used as a Matrix-Builder for the controlled release of Sirolimus. Probucol binds the drug on the stent and its properties of being hydrophobic and anti-oxidative, facilitates a controlled and continuous drug release.

Resources
Product Brochure

10 years follow up clinical data of safety and efficacy in 3002 patients is published in Journal of American College of Cardiology.

In the long-term analysis at 10 years (ISAR TEST 5 trial), Polymer-free VIVO ISAR showed numerically low rates of all-cause mortality, TVR, MI and Stent Thrombosis versus DP-ZES in the subset of diabetes mellitus.

World's Longest Studied Drug Eluting Stent

Even with no polymer, VIVO ISAR showed similar results with regards to safety and efficacy when compared with DES with permanent polymer in ACS patient subset

In this long term analysis at 10 years, Polymer Free Vivo ISAR in Diabetic patients showed numerically low rates of all-cause mortality, TVR MI, and stent thrombosis versus DP-ZES

In this long term analysis at 10 years , Polymer Free Vivo ISAR showed similar efficacy and safety
profile as PP-ZES

At 5 years, outcomes of patients treated with Vivo Isar compared with durable polymer-based ZES were similar in the subgroup of STEMI.

At 5 years in diabetic patient subset , outcomes of patients treated with Vivo Isar compared with PP-
ZES were similar

At 5 years, Vivo Isar with no polymer demonstrates similar rates of definite/probable stent
thrombosis as PP-ZES

At 2 years, Vivo Isar demonstrated 43% reduction in binary restenosis in comparison to PP-ZES and
23% reduction in comparison to PP-SES

In preclinical study , Vivo Isar demonstrated ideal drug release kinetics and better endothelialisation
as compared to polymer based and conventional polymer free stent.

A rough stent surface does not increase late lumen loss after stent implantation as compared with a conventional smooth stent surface.

Thin Structural Design Concomitating with Greater DeliverabilityIdeal Strut Thickness
Racer CC is designed with thinner struts to provide the healing advantage associated with minimal vessel injury and better endothelialisation.Greater Deliverability
Racer CC with its ideal strut thickness offers optimal strength, flexibility and pushability thus ensuring precise deploymentEnhanced Biocompatibility
The trusted stent platform of Racer CC has been steadily optimized with thinner struts and cell design offering better long-term outcomes

Resources
Product Brochure

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.

Comparison of clinical outcomes at 10 years in patients treated with new-generationBP-SES versus new-generation PP-EES versus early generation SES.

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from 3 randomised trials.

At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer DES in patients with Diabetes Mellitus.

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes: a pooled analysis of individual patient data from 3 randomised trials.

At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer DES in patients with Diabetes Mellitus.

TECHNICAL DATAPRODUCT MATRIX / ORDERING INFORMATION*

*Please contact our customer care for available sizes

COMPLIANCE CHART

Sirolimus Eluting Coronary Stent System 

• 0% Low St Rate

• 2 . 4% Mace

• 1700 Patients Studied

BIOMIME

BioMimeTM is a Sirolimus Eluting Coronary Stent System with an ultra-thin (65 µm) strut thickness.

This next generation (SES) has a Novel Hybrid Design with closed cells (on both ends of the stent) & open cells (in the middle)- this allows for Morphology Mediated Expansion for adequate conformability and lesser edge dissections.

BioPoly-Biodegradable Polymer: 2µm low thickness, stable and elastic polymer.

Stent design with non-linear S links & Y connectors allowing high flexibility and adequate side branch access. Strut width variability ensures optimal radial strength.

Low balloon over hang of less than 0.5mm to minimize healthy vessel injury.

Available in more than 94 Countries worldwide with more than 500,000 stents deployed.

meriT Trials: Consistent data in more than 1,700 patients upto 5 years follow-up.

Non Inferiority to XIENCE DES proven in meriT-V: published in Eurointervention (Sep'18)

Benefits
01.Ultra-thin 65 µm strut thickness & Biodegradable Polymer-Based DES for Faster Healing.
02.Strut Width Variability for Optimal Radial Strength & Conformability.
03.Morphology Mediated Expansion for Lesser Edge Dissections .
04.Novel Hybrid Cell Design with Open Cells in the Middle for Adequate Side Branch Access